TO: Tribal Health Community

FR: Chelsea Kleinmeyer, Community Nursing Division Director



Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine: 


As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. 


CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. 


All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. 


CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. 


Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. 


Right now, these adverse events appear to be extremely rare. 


COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. 


People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider.


Tribal Health will also pause in the use of the J&J vaccine until further notice.


Tribal Health patients are encouraged to reach out to the Tribal Health COVID Hotlines with any questions or concerns at:




Tribal Health Nurses are staffing a community Hotline and Email to help answer questions and concerns including: 


  • Questions about the COVID-19 (coronavirus)
  • Help connect patients with other resources of the CSKT and the valley


CALL: 406-849-5798. 

Monday - Friday 

8:00am - 4:30pm


EMAIL: This email address is being protected from spambots. You need JavaScript enabled to view it.

Staff will respond to emails within 24 hours